Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/9393
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTikkanen, Ilkkaen
dc.contributor.authorTikkanen, Tuulaen
dc.contributor.authorCao, Zeminen
dc.contributor.authorAllen, Terri Jen
dc.contributor.authorDavis, Belinda Jen
dc.contributor.authorLassila, Markusen
dc.contributor.authorCasley, David Jen
dc.contributor.authorJohnston, Colin Ien
dc.contributor.authorBurrell, Louise Men
dc.contributor.authorCooper, Mark Een
dc.date.accessioned2015-05-15T22:28:21Z
dc.date.available2015-05-15T22:28:21Z
dc.date.issued2002-04-01en
dc.identifier.citationJournal of Hypertension; 20(4): 707-14en
dc.identifier.govdoc11910307en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/9393en
dc.description.abstractThe effects of combined inhibition of neutral endopeptidase (NEP) with either angiotensin-converting enzyme (ACE), or endothelin-converting enzyme (ECE) on blood pressure, urinary albumin excretion and heart weight were explored in experimental diabetes.Streptozotocin-induced diabetic Sprague-Dawley rats were treated with vehicle, the NEP/ACE inhibitor S 21402, the NEP/ECE inhibitor CGS 26303, the NEP inhibitor SCH 42495, the ACE inhibitor captopril or the endothelin receptor antagonist bosentan for 4 weeks.Blood pressure was measured by tail-cuff method and radiotelemetry. Albuminuria, plasma renin activity and plasma atrial natriuretic peptide (ANP) were determined by radioimmunoassay. NEP binding was assessed by in vitro quantitative autoradiography. Metabolic and biochemistry parameters including food intake, 24-h urine volume, plasma glucose, glycated hemoglobin, glomerular filtration rate (GFR) and urinary sodium excretion were also determined.Mean blood pressure over the 4-week study period after commencement of treatment was reduced to a similar extent by a range of treatments including the ACE inhibitor, NEP/ACE inhibitor, endothelin receptor antagonist, NEP/ECE inhibitor, but not the NEP inhibitor, compared with vehicle-treated diabetic rats. Heart to body weight ratio in diabetic rats was only reduced by the NEP/ACE and the NEP/ECE inhibitor. Increased albuminuria in diabetic rats (1.1 times/divided by 1.2 mg/day) was reduced by the NEP/ACE (0.6 times/divided by 1.2 mg/day) and the NEP/ECE inhibitors (0.4 times/divided by 1.2 mg/day). Renal NEP was reduced by the NEP/ACE inhibitor (35 +/- 4%) or NEP/ECE inhibitor (38 +/- 4%) as well as by the pure NEP inhibitor (27 +/- 4%) compared with the untreated diabetic group. Other abnormal metabolic and biochemical parameters in diabetic rats were not influenced by any drug treatment.Combined inhibition of NEP/ACE or NEP/ECE confers beneficial effects on blood pressure, albuminuria and heart to body weight ratio in experimental diabetes.en
dc.language.isoenen
dc.subject.otherAlbuminuria.drug therapyen
dc.subject.otherAngiotensin-Converting Enzyme Inhibitors.administration & dosage.pharmacologyen
dc.subject.otherAnimalsen
dc.subject.otherAspartic Acid Endopeptidases.antagonists & inhibitorsen
dc.subject.otherAtrial Natriuretic Factor.blooden
dc.subject.otherBlood Pressure.drug effectsen
dc.subject.otherDiabetes Mellitus, Experimental.drug therapy.enzymology.pathology.physiopathologyen
dc.subject.otherDrug Interactionsen
dc.subject.otherEndothelin Receptor Antagonistsen
dc.subject.otherHeart.drug effectsen
dc.subject.otherKidney.drug effects.physiopathologyen
dc.subject.otherMaleen
dc.subject.otherMetalloendopeptidasesen
dc.subject.otherMyocardium.pathologyen
dc.subject.otherNeprilysin.antagonists & inhibitorsen
dc.subject.otherOrgan Size.drug effectsen
dc.subject.otherOrganophosphonates.administration & dosage.blood.pharmacologyen
dc.subject.otherProtease Inhibitors.administration & dosage.blood.pharmacologyen
dc.subject.otherRatsen
dc.subject.otherRats, Sprague-Dawleyen
dc.subject.otherRenin.blooden
dc.subject.otherSulfonamides.administration & dosage.pharmacologyen
dc.subject.otherTetrazoles.administration & dosage.blood.pharmacologyen
dc.titleCombined inhibition of neutral endopeptidase with angiotensin converting enzyme or endothelin converting enzyme in experimental diabetes.en
dc.typeJournal Articleen
dc.identifier.journaltitleJournal of Hypertensionen
dc.identifier.affiliationDepartment of Medicine, University of Melbourne, Austin and Repatriation Medical Centre, Heidelberg, Victoria, Australiaen
dc.description.pages707-14en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/11910307en
dc.type.austinJournal Articleen
local.name.researcherBurrell, Louise M
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptCardiology-
crisitem.author.deptGeneral Medicine-
crisitem.author.deptMedicine (University of Melbourne)-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

38
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.